SOMATOM go.Up; SOMATOM go.Now; SOMATOM go.All; SOMATOM go.Top; SOMATOM go.Sim; SOMATOM go.Open Pro; SOMATOM X.cite; SOMATOM X.ceed
Siemens Medical Solutions USA, Inc. • Radiology • 03/26/2024
Device Purpose
The Siemens SOMATOM go. and X. Platform CT systems, utilizing a single rotating X-ray tube-detector and the SOMARIS/10 syngo CT VB10 software, are designed to produce high-quality cross-sectional images for a broad range of diagnostic and therapeutic applications. These systems incorporate advanced hardware like the FAST 3D camera and software features such as ZeeFree artifact reduction and myNeedle Guide to enhance image quality, workflow efficiency, and support for interventional procedures, with performance validated through rigorous non-clinical testing.
Summary
The Siemens SOMATOM go. Platform and SOMATOM X. Platform are Computed Tomography (CT) X-ray systems designed to generate and process cross-sectional images of patients for diagnostic, treatment, and radiation therapy planning purposes, including low-dose lung cancer screening and aid in therapeutic interventions. These single-source, fan-beam systems utilize a continuously rotating tube-detector assembly (featuring Stellar, StellarInfinity, Chronon, Athlon, or Vectron technologies depending on the model) and produce DICOM-format images. The core functionality is managed by the SOMARIS/10 syngo CT VB10 software, a command-based platform for patient and data management, scan control, image reconstruction (including iterative methods like ADMIRE, SAFIRE, iMAR), and image evaluation, with interfaces for various post-processing applications. Key system features include advanced detector technology, tin filtration, DirectDensityTM, and workflow enhancements like Scan&GO with mobile tablet operation. The new software version, syngo CT VB10, builds upon the previous VA40 version by introducing and modifying several hardware and software functionalities across the various SOMATOM models. Notable updates include an enhanced FAST 3D Camera for automated patient positioning, ZeeFree for reducing breath-hold related image artifacts, myNeedle Guide with AI-based needle detection for interventional procedures, DirectBreathhold for synchronized scanning with external gating devices, and updates to myExam Companion and Recon&GO for improved workflow and reconstruction. Non-clinical performance testing, including phantom studies and bench tests, verified the accuracy and efficacy of these modifications. For instance, the FAST 3D camera demonstrated comparable positioning accuracy, ZeeFree effectively reduced artifacts without degrading image quality, and myNeedle Detection achieved a high success rate in identifying needle tips, thereby streamlining interventional workflows.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. What is the quantitative impact of the ZeeFree software feature on image noise and spatial resolution compared to standard reconstruction techniques in clinical cardiac imaging scenarios with varying degrees of patient motion?; How does the accuracy of the myNeedle Guide's automatic needle detection algorithm (90.76% in bench tests) translate to diverse clinical settings, particularly with different needle types, patient anatomies, and imaging protocols?; What are the specific improvements in workflow efficiency (e.g., time savings, reduction in operator steps) attributed to the 'FAST Integrated Workflow' and 'myExam Companion' modifications in the syngo CT VB10 software across different SOMATOM platform models?; Can the DirectDensityTM feature, which provides relative electron and mass density, be reliably used for quantitative material decomposition or tissue characterization beyond standard Hounsfield units, and how does it compare to dual-energy CT approaches on these single-source systems?; Given the introduction of the 'Multi-Purpose Table (Vitus)' with an extended gantry-table distance for some SOMATOM X. Platform models, what is the impact on scatter radiation profiles and overall image quality, especially for larger patients or when using ancillary equipment in interventional procedures?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Post-§524B but no clear network capability detected
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of SBOM, ML-BOM, SaaSBOM, HBOM detected in AI-generated device summary.
• Cybersecurity risk assessment not referenced in AI-generated device summary. FDA cybersecurity guidance (2023) expects this for cyber devices.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly